USANA Health Sciences (NYSE:USNA) Shares Up 3.8% - What's Next?

Shares of USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) were up 3.8% during trading on Wednesday . The stock traded as high as $27.17 and last traded at $27.25. Approximately 42,753 shares traded hands during trading, a decline of 60% from the average daily volume of 107,029 shares. The stock had previously closed at $26.26.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on USNA shares. DA Davidson dropped their target price on shares of USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday, February 27th. Sidoti downgraded USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 18th. Finally, StockNews.com cut USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Friday, February 14th.

USANA Health Sciences Stock Down 1.1 %

The firm's fifty day moving average price is $31.15 and its 200 day moving average price is $35.08. The stock has a market cap of $526.37 million, a PE ratio of 9.84, a P/E/G ratio of 0.93 and a beta of 0.98.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The firm had revenue of $213.61 million during the quarter, compared to analyst estimates of $208.82 million. As a group, analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Remove Ads

Insider Buying and Selling

In other news, CEO Jim Brown sold 5,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $29.47, for a total value of $147,350.00. Following the completion of the sale, the chief executive officer now owns 15,716 shares in the company, valued at approximately $463,150.52. This trade represents a 24.14 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Mulham Mulham sold 3,234 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $32.98, for a total transaction of $106,657.32. Following the completion of the sale, the insider now directly owns 12,775 shares of the company's stock, valued at approximately $421,319.50. The trade was a 20.20 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 15,920 shares of company stock worth $500,285. Insiders own 0.33% of the company's stock.

Hedge Funds Weigh In On USANA Health Sciences

Several hedge funds have recently bought and sold shares of the business. Barclays PLC lifted its stake in USANA Health Sciences by 111.9% in the third quarter. Barclays PLC now owns 27,737 shares of the company's stock worth $1,052,000 after acquiring an additional 14,647 shares during the period. Rhumbline Advisers increased its position in shares of USANA Health Sciences by 39.8% in the 4th quarter. Rhumbline Advisers now owns 49,390 shares of the company's stock valued at $1,773,000 after acquiring an additional 14,068 shares during the period. Principal Financial Group Inc. lifted its position in USANA Health Sciences by 2.8% during the 4th quarter. Principal Financial Group Inc. now owns 53,603 shares of the company's stock worth $1,924,000 after acquiring an additional 1,480 shares during the period. Pzena Investment Management LLC grew its stake in USANA Health Sciences by 3.6% during the 4th quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company's stock valued at $39,015,000 after purchasing an additional 37,466 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of USANA Health Sciences by 4.5% in the third quarter. Geode Capital Management LLC now owns 297,120 shares of the company's stock valued at $11,269,000 after purchasing an additional 12,898 shares during the period. Institutional investors own 54.25% of the company's stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.